Under construction – not a live service
Sign in
Taking people in AustraliaPhase 2

DSP107 with atezolizumab compared with fruquintinib in advanced colorectal cancer

Compares DSP107 plus atezolizumab with fruquintinib in adults with advanced microsatellite stable colorectal cancer.

Key facts

Who runs it
Kahr Bio Australia Pty Ltd
Where
Bedford Park, Camperdown, Clayton, Footscray, Heidelberg, Melbourne, Nedlands, Port Macquarie, Saint Albans, South Brisbane, Westmead, and Woodville, AustraliaSee the 12 sitesAlso in 1 other country, 6 sites
Trial code
Registry title
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
Status
Recruiting
Phase
Phase 2
People taking part
90 people, planned
Started
16 Jan 2026
Expected to end
30 Apr 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • DSP107 + Atezolizumab
  • Fruquintinib
Record updated
20 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced colorectal cancer that cannot be removed by surgery and is microsatellite stable (MSS) or has proficient mismatch repair (pMMR). It compares DSP107 with atezolizumab against fruquintinib.

Age
18 years or older, with a life expectancy of more than 3 months.
Sex
All sexes can join.
Disease stage
Colorectal cancer confirmed under the microscope, inoperable, MSS and/or pMMR. It has progressed on, or the person cannot tolerate, specified therapies. Measurable disease per RECIST v1.1.
Earlier treatment
No more than 3 lines of earlier therapy. Earlier treatment with checkpoint inhibitors (CPIs) is allowed.
Biomarker or test result
MSS and/or pMMR tumour.

Main reasons for not taking part

  • Brain or spinal cord (CNS) metastases, unless stable 2 months after definitive therapy with steroids
  • Unresolved side effects of Grade 2 or higher from earlier cancer treatment
  • Past or current autoimmune disease or immune deficiency
  • Another cancer within 3 years before the first study treatment cycle
  • Allergy to any of the test compounds

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Are ≥ 18 years of age with a life expectancy of > 3 months
  • Participants with histologically confirmed, inoperable, MSS and/or pMMR CRC which has progressed to, or is intolerant to, specified therapies (and has received prior treatment with no more than 3 lines of therapy)
  • Measurable disease per RECIST v1.1

Who cannot take part

  • Central nervous system (CNS) metastases unless stable 2 months post definitive therapy with steroids
  • Unresolved AEs of Grade 2 or higher from prior anticancer therapy
  • Current or recent treatment with certain therapies including specified anticancer treatments, modulators of CYP3A4 and immunomodulating therapies (prior treatment with CPIs is not exclusory)
  • Past or current history of autoimmune disease or immune deficiency
  • History of other malignancy within 3 years of first study treatment cycle
  • Known allergy or hypersensitivity to any of the test compounds, materials, or contraindication to test product
  • Clinically significant abnormal laboratory safety tests

Where in Australia

Also in 1 other country, 6 sites

  • Flinders Medical Centre SABedford Park, AustraliaContact: Christos Stelios Karapetis, Prof (principal investigator)Taking people
  • Chris O'Brien LifehouseCamperdown, AustraliaContact: Sarah Isabella MacKenzie Sutherland, Dr (principal investigator)Taking people
  • Monash HealthClayton, AustraliaContact: David Kar Wah Lau, Dr (principal investigator)Taking people
  • Footscray Hospital - Western HealthFootscray, AustraliaContact: Peter Gibbs, Prof (principal investigator)Taking people
  • Austin HealthHeidelberg, AustraliaContact: Niall Christopher Tebbutt, Prof (principal investigator)Taking people
  • Alfred HospitalMelbourne, AustraliaContact: Andrew Mark Meurisse Haydon, Dr (principal investigator)Taking people
  • Sir Charles Gairdner HospitalNedlands, AustraliaContact: Rajiv Narayan Shinde, Dr (principal investigator)Taking people
  • Port Macquarie Base Hospital (Mid North Coast Cancer Institute), Wrights Road,Port Macquarie, AustraliaContact: Dr Stephen Donald Begbie (principal investigator)Taking people
  • Sunshine Hospital - Western HealthSaint Albans, AustraliaContact: Peter Gibbs, Prof (principal investigator)Taking people
  • Icon Cancer CentreSouth Brisbane, AustraliaContact: Jermaine lan George Coward, A/Prof (principal investigator)Taking people
  • Westmead HospitalWestmead, AustraliaContact: Adnan Mahmood Nagrial, Associate Professor (principal investigator)Taking people
  • The Queen Elizabeth HospitalWoodville, AustraliaContact: Timothy Jay Price, Dr (principal investigator)Taking people

About the trial

What the trial wants to find out

This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable (MSS). Participants will be randomly assigned to receive one of the two treatments, and researchers will monitor how well the cancer responds, how safe the treatments are, and how the body processes them. The study hopes to show that the new combination can improve outcomes for patients with this type of colorectal cancer.

The 2 groups in the trial

  • DSP107 in combination with AtezolizumabTreatment being tested

    DSP107 10 mg/kg IV on Days 1, 8, and 15 of each 28-day cycle. Atezolizumab 1680 mg IV on Day 1 of each 28-day cycle.

    Treatment: DSP107 + Atezolizumab

  • FruquintinibExisting treatment, for comparison

    Participants will receive fruquintinib orally in 28-day cycles, for up to 24 cycles (96 weeks), or until disease progression, unacceptable toxicity, or study withdrawal.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Randomized, Open-label, Phase 2b Study to Compare the Efficacy of DSP107 in Combination With Atezolizumab Versus Fruquintinib in Patients With Advanced Microsatellite Stable Colorectal Cancer
Plain-language title
DSP107 with atezolizumab compared with fruquintinib in advanced colorectal cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
20 August 2026